This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Market Chatter: Helixmith Chooses PRA Health Sciences for Phase Three Trials of Engensis MT
ICON Public : Posts Higher Q2 Results from Year Ago, Updates Guidance -- Stock Down 3% After-Hours MT
PRA HEALTH SCIENCES : Mizuho Securities Starts PRA Health Sciences at Neutral with $169 Price Target MT
PRA Health Sciences, Inc.(NasdaqGS:PRAH) dropped from S&P Global BMI Index CI
PRA Health Sciences, Inc.(NasdaqGS:PRAH) dropped from S&P TMI Index CI
PRA Health Sciences, Inc.(NasdaqGS:PRAH) dropped from S&P 1000 CI
PRA Health Sciences, Inc.(NasdaqGS:PRAH) dropped from S&P 400 Health Care CI
PRA Health Sciences, Inc.(NasdaqGS:PRAH) dropped from S&P 400 CI
PRA Health Sciences, Inc.(NasdaqGS:PRAH) dropped from S&P Composite 1500 CI
PRA Health Sciences, Inc. Announces Board Changes CI
PRA Health Sciences, Inc.(NasdaqGS:PRAH) dropped from NASDAQ Composite Index CI
PRA Health Sciences, Inc.'s Equity Buyback announced on August 30, 2019, has expired. CI
ICON Public Limited Company completed the acquisition of PRA Health Sciences, Inc.. CI
PRA Health Sciences, Inc.(NasdaqGS:PRAH) dropped from NASDAQ Biotechnology Index CI
Allscripts Healthcare : PRA Health Sciences, Allscripts' Veradigm Plan Clinical Research Network Based on Electronic Health Records MT
Veradigm and PRA Health Sciences Partner to Create the Industry’s Leading EHR-Based Clinical Research Network CI
ICON Public : Prices $500 Million of Senior Secured Notes MT
ICON Public : Unit to Raise $2 Billion via Senior Secured Notes Offering MT
ANALYST RECOMMENDATIONS : Amgen, Biogen, Halfords, J Sainsbury, Uber... Our Logo
CORRECTION : Mizuho Securities Maintains Price Target for PRA Health Sciences at $169, Reiterates Neutral Rating MT
PRA HEALTH SCIENCES : Mizuho Securities Adjusts PRA Health Sciences PT to $155 From $169, Maintains Neutral Rating MT
Pra Health Sciences, Inc. Pioneers Connecting Clinical Trial Patients with Their Real-World Data with Synoma CI
MOVES-Deutsche Bank hires investment banking veteran Priyanka Verma in healthcare push RE
PRA HEALTH SCIENCES : Truist Securities Downgrades PRA Health Sciences to Hold From Buy; Price Target is $175 MT
PRA HEALTH SCIENCES : UBS Adjusts Price Target on PRA Health Sciences to $170 From $155 on ICON Deal; Neutral Rating Kept MT
Chart PRA Health Sciences, Inc.
More charts
PRA Health Sciences, Inc. is a United States-based company. The Company is a contract research organization. It is engaged in providing outsourced clinical development and data solution services to the biotechnology and pharmaceutical industries. The Company focused on oncology, immunology, central nervous system, inflammation, respiratory, cardiometabolic, and infectious diseases. It operates through two segments: Clinical Research and Data Solutions. The Clinical Research segment provides services across the spectrum of clinical development programs. The Data Solutions segment provides data, analytics, technology and consulting solutions to the life sciences market. The Company offer clinical development service offerings, which include functional outsourcing services, traditional and project based clinical trial services.
More about the company
  1. Stock Market
  2. Equities
  3. PRAH Stock
  4. News PRA Health Sciences, Inc.
  5. PRA Health Sciences : Earnings Flash (PRAH) PRA HEALTH SCIENCES Reports Q1 EPS $1.35